|
|
|
By Lisa Cozza, Tunnell Consulting
|
Operational readiness will separate the leaders from the laggards, whether you lead a pharma/biotech innovator, CDMO, or a combination of both.
|
|
|
|
|
|
|
|
|
|
|
By Giuseppe Coppola and Pelin Bilgin — Novartis, and Simon Pannatier — a-connect
|
A team at Novartis developed models to address the often-overlooked challenge of clinical trial comparator sourcing, a weak link that can derail trials.
|
|
|
|
|
|
|
|
|
|
Remote Patient Monitoring Using Mobile Health Technology
|
White Paper | By Dominique G. Stuijt, Eva EM van Doeveren, Milan Kos, et al., CHDR
|
This study investigates the attitudes of cancer patients towards the adoption of mHealth technologies, including applications and wearable devices, for monitoring purposes during or after their treatment.
|
|
|
|
Enabling Investment In Community Hospitals To Improve Patient Access
|
Article | By Dr. Sanjay Srivastava, Cell & Gene therapy lead; Rahul Mirchandani, Life Sciences at Accenture Life Sciences, and Joe DePinto, McKesson
|
Learn why enabling community hospitals to alleviate system constraints would usher a change in the future of cell and gene therapy delivery.
|
|
|
|
|
CLINICAL TRIALS SOLUTIONS
|
|
|
|
|
|
|
|
|
Advancing the Future of Cell & Gene Therapy
|
This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines.
Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now
|
|
|
Connect With Cell & Gene: |
|
|
|